SEHK Growth Companies With High Insider Ownership October 2024

In This Article:

As global markets navigate the complexities of geopolitical tensions and economic shifts, Hong Kong's Hang Seng Index has shown resilience, climbing 10.2% in a holiday-shortened week. This performance highlights investor optimism amid Beijing's supportive measures, setting a promising backdrop for growth companies with high insider ownership. In such a market environment, stocks that combine robust growth potential with significant insider ownership may offer unique insights into management confidence and long-term value creation strategies.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

Laopu Gold (SEHK:6181)

36.4%

32.7%

Akeso (SEHK:9926)

20.5%

52.6%

Fenbi (SEHK:2469)

33.1%

22.4%

Xiamen Yan Palace Bird's Nest Industry (SEHK:1497)

26.7%

23.8%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.8%

69.8%

Pacific Textiles Holdings (SEHK:1382)

11.2%

37.7%

DPC Dash (SEHK:1405)

38.1%

104.2%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

109.2%

Beijing Airdoc Technology (SEHK:2251)

29.1%

93.4%

Zhejiang Leapmotor Technology (SEHK:9863)

15%

69.7%

Click here to see the full list of 47 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Beauty Farm Medical and Health Industry

Simply Wall St Growth Rating: ★★★★★☆

Overview: Beauty Farm Medical and Health Industry Inc. (SEHK:2373) operates in the healthcare sector, focusing on medical and health services, with a market cap of approximately HK$4.08 billion.

Operations: The company's revenue is derived from four main segments: Aesthetic Medical Services (CN¥851.81 million), Subhealth Medical Services (CN¥125.69 million), Beauty and Wellness Services - Direct Stores (CN¥1.14 billion), and Beauty and Wellness Services - Franchisee and Others (CN¥131.48 million).

Insider Ownership: 33.9%

Earnings Growth Forecast: 20.2% p.a.

Beauty Farm Medical and Health Industry is trading significantly below its estimated fair value, suggesting potential undervaluation. The company reported a modest increase in earnings for the first half of 2024, with sales reaching CNY 1.14 billion. Earnings are projected to grow significantly at over 20% annually, outpacing the Hong Kong market average. Recent board changes include appointing Mr. Hu Tenghe as a non-executive director, bringing extensive capital markets experience to the team.